

ELECSYS® HIV COMBI PT 4TH GENERATION (AG+AB TEST)

Detect HIV early across groups and subtypes

Don't let HIV elude capture

HIV remains a deadly virus that continues to evolve at a rapid rate. To ensure HIV doesn't go undetected, it's critical that screening assays recognize all variant forms of HIV.

Control starts with earlier detection

With the Elecsys® HIV combi PT assay, the HIV-1 p24 antigen and antibodies to HIV-1 and HIV-2 can be detected simultaneously in one determination. This leads to improved sensitivity and therefore a shorter diagnostic window as compared to anti-HIV assays. Initiating therapy earlier may lead to a better control of the disease and improved survival rates.[1]

Improve patient management

- 100% clinical sensitivity for HIV-1
- 99.94% specificity in clinical routine, pregnancy and pediatrics testing

Reliably diagnose HIV infection from all over the world

- Recognition of all known HIV groups and subtypes
- High sensitivity for HIV-2 antibodies in positive populations and HIV-2 endemic regions

HIV continues to impact lives

More than **1.2 million** Americans live with HIV.[2]

40,000 HIV infections are diagnosed in the U.S. every year.[2]

13% of HIV-infected Americans don't even know they are infected.[2]

High sensitivity and specificity to accurately identify HIV

Individuals positive for antibodies positive to HIV-1[3]

HIV-1 antibody positive cohorts	Clinical sensitivity
Adults (n=1225)	100%
Pediatrics (n=50)	100%
Pregnant (n=60)	100%
HIV Group M subtypes (n=75)	100%
Antibody positive adults (n=50)	100%

Ability to detect a wide range of HIV-1 Group M subtypes[3]

Subtype (n=15)	Elecsys® HIV combi PT	Reference method
A	15/15	15/15
B	15/15	15/15
C	15/15	15/15
D	15/15	15/15
CRF01_AE	15/15	15/15
CRF02_AG	10/10	10/10

Low-risk population[3]

Cohort	Overall specificity
Adults (n=6050)	99.94%
Pediatrics (n=591)	
Pregnant women negative for HIV (n=202)	

Individuals positive or at high risk for HIV-2[3]

Specimen population	Clinical sensitivity
Known positive for antibodies to HIV-2	100% (211/211)
HIV-2 endemic regions	99.64% (705/706)

Ability to detect HIV-1 group O[3]

Cohort sensitivity	Sensitivity
Group O (n=42)	100%

Fast turnaround time. Run time is one of the fastest in the industry.[4,5,6,7]



For more information, contact your laboratory or visit **www.usdiagnostics.roche.com**

Roche Diagnostics
9115 Hague Road
Indianapolis, IN 46256
www.cobas.com
1-800-779-7616

SOURCES
[1]Jonsson M. et al. HAART initiation and clinical outcomes: insights from the CASCADE cohort of HIV-1 seroconverters on "When to Start." XVIII International AIDS Conference (AIDS 2010). Vienna, July 18-23, 2010. Abstract THLBB201.
[2]"Trends in U.S. HIV Diagnoses, 2005-2014," CDC Fact Sheet, February 2016.
[3]Elecsys® HIV combi PT, package insert.
[4]Advia Centaur and Centaur XP 1.697136 rev B (downloaded June 8, 2017), http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/PremarketApprovalsPMAs/ucm450386.htm.
[5]Architect HIV AG/Ab/combo insert FDA clearance https://www.cdc.gov/hiv/pdf/testing/hiv-tests-laboratory-use.pdf (downloaded June 8, 2017),
[6]Ortho Anti-HIV 1+2 package insert http://apps.orthoclinical.com/TechDocs/TechDocSearch.aspx?c%CE%BCture=en-us&tID=0&region=US.
[7]BioPlex® 2200 System HIV Ag-Ab, Instructions for Use, Ref 665-3455, https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/PremarketApprovalsPMAs/UCM455847.pdf (accessed August 2, 2017); supplemental form, the next-generation HIV testing, bio-rad.com.